Paul Nouri, CFP
Hedge fund manager, long/short equity, healthcare

LipoScience Has Become Too Cheap To Ignore

Of the approximately $50 billion in IPOs this year, LipoScience (NASDAQ:LPDX) is indisputably one of the most disappointing and underperforming. After being priced at $9 in January of this year, the shares quickly rose to $11 and have since fallen nearly 70%.

Every quarter this year has brought on more disappointment. While the company's operating expenses will increase nearly 25% in 2013 over the prior year, sales are expected to decline approximately 5%. Also, average selling price for the test has declined for three consecutive years. So what reason could I have to recommend investors purchase shares of this diagnostic company?

Background

LipoScience is a diagnostic company that develops and markets tests to identify the presence of cardiac...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
WITH SEEKING ALPHA PRO, INVESTORS CAN ALSO:
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
Money back guarantee. Seeking Alpha PRO members receive a no-questions-asked refund for membership on months paid and not used. Details